NCT04575259已完成2 期
Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 132
- 试验地点
- 10
- 主要终点
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
研究概览
简要总结
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.
详细描述
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previous completion of participation in the ANAVEX2-73-PDD-001 study.
- •Caregivers and subjects (or legal representative) must understand and have signed approved informed consent.
- •Caregivers and subjects (or legal representative) must be able to understand study requirements and be willing to follow instructions.
- •Stable regimen of anti-Parkinson's disease medications (including levodopa, dopamine agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable for at least 4 weeks prior to Baseline.
- •Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable for a minimum of 8 weeks prior to joining this study.
- •Subjects with history of depression on antidepressant medications will be allowed if depression is controlled and they have been on a stable daily dose of the antidepressant for ≥8 weeks before Baseline.
- •Contraception: Women of childbearing potential must use an acceptable method of contraception starting 4 weeks prior to study drug administration and for a minimum of 4 weeks after study completion. Otherwise, women must be postmenopausal (at least one year absence of vaginal bleeding or spotting) as confirmed by FSH greater than or equal to 40 mIU/mL or 40 IU/L or be surgically sterile.
- •Men with a potentially fertile partner must have had a vasectomy or be willing to use an acceptable method of contraception for the duration of the study and for 3 months after study drug discontinuation.
排除标准
- •History of any significant neurologic or psychiatric disorder other than PD that can contribute to cognitive impairment.
- •Any other condition or clinically significant abnormal findings on the physical or neurological examination, medical and psychiatric history, at screening or at baseline that, in the opinion of the Investigator, would make the subject unsuitable for the study.
- •Potential symptomatic causes of cognitive impairment including but not limited to
- •abnormal thyroid function test at screening (TSH)
- •abnormal B12 level at screening
- •MRI findings (by history) pointing to a potential symptomatic cause of cognitive dysfunction, including significant vascular changes, or communicating hydrocephalus.
- •Treatment with memantine or amantadine. If appropriate the drugs can be discontinued for a minimum of 4 weeks prior to enrollment.
- •History of depression as measured by Beck Depression Inventory score >17 at screening.
- •Treatment with any other investigational drug or device within 4 weeks prior to screening.
- •Smoking > 1 pack of cigarettes per day (as assessed for the 4 weeks prior to screening).
- •Women who are pregnant or lactating.
- •Known allergy or sensitivity to ANAVEX2-73 or any of its components.
- •Suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) of type 4 or type 5, or any suicidal behavior, in the past 6 months. Type 4 indicates active suicidal ideation with some intent to act, without a specific plan. Type 5 indicates active suicidal ideation with a specific plan and intent.
- •Use of centrally acting anticholinergic drugs during the 4 weeks before enrollment.
- •Medications used for overactive bladder will be allowed provided that the regimen has been stable 4 weeks prior to enrollment.
- •Treatment with any dopamine receptor blocking medications with the exception of low dose quetiapine (≤50 mg/day). Pimavanserin (≤34 mg/day) will be allowed.
- •History of neurosurgical intervention (e.g., deep brain stimulation) for PD.
- •Unpredictable motor fluctuations that would interfere with administering cognitive assessments in the ON state.
研究组 & 干预措施
ANAVEX2-73 Active
Experimental
Oral capsules
干预措施: ANAVEX2-73 (Drug)
结局指标
主要结局
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
时间窗: 48 weeks
To continue assessing the safety and tolerability of ANAVEX2-73
次要结局
- MDS-UPDRS Part III Total Score (Motor Scores)(48 weeks)
- MoCA (Montreal Cognitive Assessment)(48 weeks)
- RSBDQ (REM Sleep Behavior Disorder Screening Questionnaire)(48 weeks)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004Alzheimer DiseaseNCT04314934Anavex Life Sciences Corp.300
已完成
2 期
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT02756858Anavex Life Sciences Corp.21
进行中（未招募）
2 期
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)FSHDFSHD1FSHD2FMDFMD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Dystrophies, Facioscapulohumeral MuscularDystrophy, Facioscapulohumeral MuscularFacioscapulohumeral Muscular Dystrophy 1Facioscapulohumeral Muscular Dystrophy 2Facio-Scapulo-Humeral DystrophyAtrophy, FacioscapulohumeralAtrophies, FacioscapulohumeralFacioscapulohumeral AtrophyMuscular DystrophiesMuscular Dystrophy, FacioscapulohumeralFSH Muscular DystrophyLandouzy Dejerine DystrophyLandouzy-Dejerine Muscular DystrophyDystrophies, Landouzy-DejerineDystrophy, Landouzy-DejerineLandouzy-Dejerine SyndromeMuscular Dystrophy, Landouzy DejerineFSHProgressive Muscular DystrophyNCT06547216Avidity Biosciences, Inc.84
终止
2 期
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT03654755Asana BioSciences162
终止
2 期
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT03407482Genentech, Inc.160